StudyFinder

A RANDOMIZED PHASE III STUDY OF IBRUTINIB PLUS OBINUTUZUMAB VERSUS IBRUTINIB PLUS VENETOCLAX AND OBINUTUZUMAB IN UNTREATED OLDER PATIENTS (≥ 70 YEARS OF AGE) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Status: Recruiting

I'm interested

This study is NOT accepting healthy volunteers

Conditions:

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Contact(s): Ava Athmann - ava.athmann@parknicollet.com

Principal Investigator: Birendra Kumar

Phase: Phase III

IRB Number: 0123456789

System ID: NCT03737981

Back

A RANDOMIZED PHASE III STUDY OF IBRUTINIB PLUS OBINUTUZUMAB VERSUS IBRUTINIB PLUS VENETOCLAX AND OBINUTUZUMAB IN UNTREATED OLDER PATIENTS (&#8805; 70 YEARS OF AGE) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)